Geneoscopy Prepares Launch of FDA-approved At-home RNA Colorectal Cancer Screening Test

Geneoscopy Prepares Launch of FDA-approved At-home RNA Colorectal Cancer Screening Test

Source: 
Medical Devices and Diagnostics Industry
snippet: 

The St. Louis, MO-based test has 94% sensitivity for colorectal cancer detection. Colosense said it aims to transform gastrointestinal diagnostics, leveraging RNA technology for higher accuracy and ease of use.